RET and thyroid gland carcinoma: Selpercatinib and pralsetinib are a kinase inhibitor that blocks a type of enzyme (kinase) and prevents the proliferation of RET-altered non-small cell lung cancer (NSCLC) and certain types of thyroid cancer, including MTC [14].